Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Key Role of MicroRNA in the Regulation of Granulocyte Macrophage Colony-stimulating Factor Expression in Murine Alveolar Epithelial Cells (AEC) during Oxidative Stress

ABSTRACT: A genome wide microarray identified 19 candidate miRNA altered in primary AEC during oxidative stress with reversal by treatment with GM-CSF. Three of these microRNA (miR 133a, miR133a* and miR133b) are also predicited to bind the GM-CSF 3 UTR.

ORGANISM(S): Mus musculus

PROVIDER: GSE56687 | GEO | 2014/04/11

SECONDARY ACCESSION(S): PRJNA244320

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Key Role of MicroRNA in the Regulation of Granulocyte Macrophage Colony-stimulating Factor Expression in Murine Alveolar Epithelial Cells (AEC) during Oxidative Stress

Project description:A genome wide microarray identified 19 candidate miRNA altered in primary AEC during oxidative stress with reversal by treatment with GM-CSF. Three of these microRNA (miR 133a, miR133a* and miR133b) are also predicited to bind the GM-CSF 3 UTR. 4 samples. Primary murine alveolar epithelial cells were isolated and subjected to room air or 80% oxygen in the presence or absence of recombinant murine GM-CSF (20 ng/ml). Total RNA was extracted and quality checked (260/280>2 and 260/230 > 1.6). Mouse genome microRNA analysis (MAM3200) was performed by SABioscience.

2014-04-11 | E-GEOD-56687 | biostudies-arrayexpress

Transcription profiling time series of mouse bone marrow macrophages treated with macrophage colony stimulating factor or granulocyte colony stimulating factor

Project description:BM monocytes were treated with 20ug/ml of M-CSF (macrophage colony stimulating factor) or GM-CSF (granulocyte monocyte colony stimulating factor) for 0, 6, 12 hours before harvesting RNA for analysis

2008-11-01 | E-MEXP-1803 | biostudies-arrayexpress

Transcriptional profiling of human macrophages differentiated with macrophage colony-stimulating factor (M-CSF) and/or granulocyte-macrophage colony-stimulating factor (GM-CSF)

Project description:In this study, we compared human monocytes differentiated for 7 days with M-CSF and/or GM-CSF. A comparison of the different macrophage populations was made using microarray profiling. Threshold: 1.0 . Logbase: 2 . Technology: Agilent.SingleColor.14850. Normalization: Shift to 75 percentile . Baseline Transformation: median of all samples . FlagSettings:. Feature is not Uniform:A. Feature is a population outlier:A. Feature is Saturated:A. Feature is not above background:M. Feature is not positive and significant:M.

2012-03-20 | E-MTAB-791 | biostudies-arrayexpress

Expression data of colony-stimulating factor (CSF) grown bone marrow derived cells

Project description:Granulocyte-Macrophage colony stimulating factor (GM-CSF) devlops heterogenous myeloid cell populations from bone marrow progenitor cells. In vitro generated bone marrow derived cells are excellent sources for obtaining dendritic cells or macrophages, but it is still not clear about the exact mixed population characteristics of GM-CSF grown cells. We revealed here that GM-CSF grown bone marrow cell derived attaching cells were composed of dendritic cells (GM-BMDC) as well as macrophages (GM-BMM). We compared the transcriptome profiles of these cell populations as well as M-CSF grown bone marrow derived macrophages (M-BMM). We used microarrays to detail the global profile of gene expressions between three populations of CSF-grown bone marrow derived cells: GM-CSF derived dendritic cells (GM-BMDC), GM-CSF derived macrophages (GM-BMM) and M-CSF derived macrophages (M-BMM).

2015-01-30 | GSE65425 | GEO

Transcriptional profiling of murine bone marrow-derived macrophages differentiated with macrophage colony-stimulating factor (M-CSF) and/or granulocyte-macrophage colony-stimulating factor (GM-CSF) for short term

Project description:In this study, we compared murine bone marrow monocytes differentiated for 7 days with M-CSF then BMM were cultured in the absence of M-CSF for 24hr (starved), then treated with different combinations of M-CSF, GM-CSF, TNF and Dex for 16hr. A comparison of the different macrophage populations was made using microarray profiling. Threshold: 1.0 . Logbase: 2 . Technology: Agilent.SingleColor.14868. Normalization: Shift to 75 percentile . Baseline Transformation: median of all samples . FlagSettings:. Feature is not Uniform:A. Feature is a population outlier:A. Feature is Saturated:A. Feature is not above background:M. Feature is not positive and significant:M.

2012-03-20 | E-MTAB-792 | biostudies-arrayexpress

Expression data of colony-stimulating factor (CSF) grown bone marrow derived cells

2015-01-30 | E-GEOD-65425 | biostudies-arrayexpress

Transcriptional profiling of murine bone marrow derived macrophages differentiated with macrophage colony-stimuating factor (M-CSF) or granulocyte-macrophage colony-stimulating factor (GM-CSF)

Project description:In this study, we compared murine bone marrow monocytes differentiated for 7 days with M-CSF or GM-CSF. A comparison of the different macrophage populations was made using microarray profiling. Threshold: 1.0 . Logbase: 2 . Technology: Agilent.SingleColor.14868. Normalization: Shift to 75 percentile . Baseline Transformation: median of all samples . FlagSettings:. Feature is not positive and significant:M. Feature is not above background:M. Feature is not Uniform:A. Feature is a population outlier:A. Feature is Saturated:A.

2012-03-20 | E-MTAB-790 | biostudies-arrayexpress

Murine Bone Marrow Stromal Cell Response to Granulocyte Colony-Stimulating Factor

Project description:Neutrophil homeostasis is maintained, in part, by the regulated release of neutrophils from the bone marrow. Constitutive expression of the chemokine CXCL12 by bone marrow stromal cells provides a key retention signal for neutrophils in the bone marrow through activation of its receptor CXCR4. Herein, we show that the ELR chemokines CXCL1 and CXCL2 are constitutively expressed by bone marrow endothelial cells and osteoblasts, and CXCL2 expression is induced in endothelial cells during granulocyte colony-stimulating factor (G-CSF)-induced neutrophil mobilization. Neutrophils lacking CXCR2, the receptor for CXCL1 and CXCL2, are preferentially retained in the bone marrow, reproducing a myelokathexis phenotype. Transient disruption of CXCR4 failed to mobilize CXCR2 neutrophils. However, doubly deficient neutrophils (CXCR2-/- CXCR4-/-) displayed constitutive mobilization, showing that CXCR4 plays a dominant role. Collectively, these data suggest that CXCR2 signaling is a second chemokine axis that interacts antagonistically with CXCR4 to regulate neutrophil release from the bone marrow. We used gene expression microarrays to determine the changes in osteoblasts and bone marrow endothelial cells after G-CSF treatment. 3 untreated and G-CSF-treated osteoblast samples and 4 untreated and G-CSF-treated endothelial samples.

2010-07-14 | E-GEOD-22925 | biostudies-arrayexpress

Inhaled granulocyte/macrophage-colony stimulating factor as therapy for pulmonary alveolar proteinosis.

Project description:RationaleInhaled granulocyte/macrophage-colony stimulating factor (GM-CSF) is a promising therapy for pulmonary alveolar proteinosis (PAP) but has not been adequately studied.ObjectivesTo evaluate safety and efficacy of inhaled GM-CSF in patients with unremitting or progressive PAP.MethodsWe conducted a national, multicenter, self-controlled, phase II trial at nine pulmonary centers throughout Japan. Patients who had lung biopsy or cytology findings diagnostic of PAP, an elevated serum GM-CSF antibody level, and a Pa(O(2)) of less than 75 mm Hg entered a 12-week observation period. Those who improved (i.e., alveolar-arterial oxygen difference [A-aDO(2)] decreased by 10 mm Hg) during observation were excluded. The rest entered sequential periods of high-dose therapy (250 microg Days 1-8, none Days 9-14; x six cycles; 12 wk); low-dose therapy (125 microg Days 1-4, none Days 5-14; x six cycles; 12 wk), and follow-up (52 wk).Measurements and main resultsFifty patients with PAP were enrolled in the study. During observation, nine improved and two withdrew; all of these were excluded. Of 35 patients completing the high- and low-dose therapy, 24 improved, resulting in an overall response rate of 62% (24/39; intention-to-treat analysis) and reduction in A-aDO(2) of 12.3 mm Hg (95% confidence interval, 8.4-16.2; n = 35, P < 0.001). No serious adverse events occurred, and serum GM-CSF autoantibody levels were unchanged. A treatment-emergent correlation occurred between A-aDO(2) and diffusing capacity of the lung, and high-resolution CT revealed improvement of ground-glass opacity. Twenty-nine of 35 patients remained stable without further therapy for 1 year.ConclusionsInhaled GM-CSF therapy is safe, effective, and provides a sustained therapeutic effect in autoimmune PAP. Clinical trial registered with www.controlled-trials.com/isrctn (ISRCTN18931678), www.jmacct.med.or.jp/english (JMA-IIA00013).

| S-EPMC2894410 | biostudies-literature

Murine Bone Marrow Stromal Cell Response to Granulocyte Colony-Stimulating Factor

2010-07-14 | GSE22925 | GEO